Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6316 to 6330 of 8906 results

  1. New sepsis guideline targets faster, tailored treatments to benefit patients

    Patients aged 16 or over with suspected sepsis will receive more tailored treatment under updated NICE guidance published today.

    News
    Last updated
    6 January 2026

  2. New age-based blood test thresholds recommended by NICE will help GPs catch ovarian cancer earlier

    More women with ovarian cancer could be diagnosed earlier under proposed new NICE guidance that replaces a one-size-fits-all blood test threshold with personalised, age-based criteria.

    News
    Last updated
    5 January 2026

  3. NICE recommends new treatment option for highly active multiple sclerosis

    Thousands of people living with a form of multiple sclerosis (MS) will benefit from greater treatment choice, following new guidance from NICE.

    News
    Last updated
    2 January 2026

  4. NICE announces Professor Jonathan Benger as new Chief Executive

    NICE Chairman, Sharmila Nebhrajani, today announced Professor Jonathan Benger CBE as incoming chief executive, with effect from Friday 19 December 2025 taking over from Dr Samantha Roberts.

    News
    Last updated
    2 January 2026

  5. Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma [ID1470]

    Discontinued Reference number: GID-TA10354

    Technology appraisal guidance
    Discontinued

  6. Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma multiforme [ID1466]

    Discontinued Reference number: GID-TA10355

    Technology appraisal guidance
    Discontinued

  7. Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies [ID1455]

    Discontinued Reference number: GID-TA10356

    Technology appraisal guidance
    Discontinued

  8. Nintedanib for untreated malignant pleural mesothelioma [ID1424]

    Discontinued Reference number: GID-TA10359

    Technology appraisal guidance
    Discontinued

  9. Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]

    Discontinued Reference number: GID-TA10363

    Technology appraisal guidance
    Discontinued

  10. Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy [ID1264]

    Discontinued Reference number: GID-TA10365

    Technology appraisal guidance
    Discontinued

  11. Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]

    Discontinued Reference number: GID-TA10377

    Technology appraisal guidance
    Discontinued

  12. Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]

    Discontinued Reference number: GID-TA10380

    Technology appraisal guidance
    Discontinued

  13. Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma [ID997]

    Discontinued Reference number: GID-TA10382

    Technology appraisal guidance
    Discontinued

  14. Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]

    Discontinued Reference number: GID-TA10390

    Technology appraisal guidance
    Discontinued

  15. Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]

    In development Reference number: GID-TA10391 Expected publication date: TBC

    Technology appraisal guidance
    In development